Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).

Manmeet Singh Ahluwalia, Yasmeen Rauf, Hong Li, Patrick Y. Wen, David M. Peereboom, David A. Reardon

Research output: Contribution to conferencePresentation

Original languageAmerican English
DOIs
StatePublished - May 20 2021
EventJournal of Clinical Oncology -
Duration: Jun 2 2023 → …

Conference

ConferenceJournal of Clinical Oncology
Period6/2/23 → …

Disciplines

  • Medicine and Health Sciences
  • Oncology
  • Internal Medicine

Cite this